On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma.
Kimiharu TakamatsuRyuichi MizunoYuto BabaYota YasumizuNobuyuki TanakaSuguru ShirotakeToshikazu TakedaShinya MoritaKazuhiro MatsumotoTakeo KosakaHiroshi AsanumaMasafumi OyamaShuji MikamiMototsugu OyaPublished in: International journal of clinical oncology (2021)
The on-treatment CRP-control could be the predictive factor for the efficacy of nivolumab in refractory mRCC patients.